Organogenesis Holdings Net Tangible Assets Over Time
| ORGO Stock | USD 4.04 0.01 0.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Organogenesis Holdings Performance and Organogenesis Holdings Correlation. Organogenesis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Organogenesis Holdings and related stocks such as Shuttle Pharmaceuticals, Mallinckrodt Plc, and Lucy Scientific Discovery Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHPH | 249.7 K | 249.7 K | 249.7 K | 249.7 K | 249.7 K | 249.7 K | (70.9 K) | 27.5 K | 27.5 K | (1.7 M) | (1.7 M) | (1.6 M) | 7.7 M | 8.8 M | 9.3 M |
| LFCR | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 148.2 M | 123.6 M | 143.2 M | 78.5 M | (19.9 M) | (17.9 M) | (17 M) |
| RDHL | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 22.4 M | 54 M | 56.6 M | 39.8 M | 45.9 M | 43.1 M | (74 M) | (62.8 M) | (62.8 M) | (56.5 M) | (53.7 M) |
| COLL | (89.3 M) | (89.3 M) | (89.3 M) | (89.3 M) | (89.3 M) | 85.1 M | 132.8 M | 104.1 M | 47.3 M | 57.9 M | (149.9 M) | (65.8 M) | (506.3 M) | (455.7 M) | (432.9 M) |
| TKNO | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (24.7 M) | (19.7 M) | 107.9 M | 107.9 M | 124.1 M | 130.3 M |
| PTPI | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (48.2 M) | (50.8 M) | (14.7 M) | 10.3 M | 10.3 M | 11.8 M | 12.4 M |
| ALKS | 143.3 M | 143.3 M | 283.6 M | 434.9 M | 823.2 M | 842.2 M | 798.4 M | 853.8 M | 887.4 M | 841.9 M | 862.9 M | 945.7 M | 913.2 M | 1.1 B | 791.1 M |
| NBIX | 60.1 M | 60.1 M | 154.4 M | 208.7 M | 208.7 M | 424.5 M | 314.9 M | 372.1 M | 480.8 M | 228.1 M | 1.1 B | 1.4 B | 1.7 B | 1.9 B | 2 B |
| ITCI | (22.1 K) | (22.1 K) | (22.1 K) | 31.6 M | 120.6 M | 476.2 M | 375.5 M | 454.4 M | 317.7 M | 195 M | 656.9 M | 417.9 M | 656.1 M | 754.5 M | 792.2 M |
| DVAX | 97.6 M | 97.6 M | 183.7 M | 183.7 M | 98.2 M | 185 M | 87.2 M | 197.3 M | 49.2 M | 3.7 M | 56.4 M | 220.2 M | 579 M | 665.9 M | 699.2 M |
Organogenesis Holdings and related stocks such as Shuttle Pharmaceuticals, Mallinckrodt Plc, and Lucy Scientific Discovery Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Organogenesis Holdings | ORGO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.04
Check out Organogenesis Holdings Performance and Organogenesis Holdings Correlation. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Organogenesis Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.